title: Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
authors.affiliation: Department of Dermatology, Hospital Clínic, University of Barcelona, Barcelona, Spain. 26305jmm@comb.es
authors.forename: Juan A
authors.initials: JA
authors.lastname: Moreno-Romero
authors.forename: Francesc
authors.initials: F
authors.lastname: Fernández-Avilés
authors.forename: Enric
authors.initials: E
authors.lastname: Carreras
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.forename: Carmen
authors.initials: C
authors.lastname: Martínez
authors.forename: José M
authors.initials: JM
authors.lastname: Mascaró
mesh_terms: D000293:Adolescent; D001549:Benzamides; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate